New HIV drug shows promise in small trial for Drug-Resistant patients

NCT ID NCT03902522

Completed Disease control Sponsor: CytoDyn, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tested an injectable drug called PRO 140 (Leronlimab) in 6 people with HIV who had developed resistance to standard medications. The goal was to see if adding PRO 140 to their current failing therapy could reduce the amount of virus in their blood. The study lasted 25 weeks and also looked at safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRO 140 (Leronlimab) - an injectable drug that blocks HIV from entering cells
What this could lead to: If successful, this could provide a new treatment option for people with HIV who have developed resistance to standard antiretroviral drugs.
What could go wrong: This is a very small early-phase trial with only 6 participants, so results may not apply broadly. The drug is tested alongside failing therapy, and long-term safety and efficacy are not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

CD02_OpenLabel Investigational Site

Palm Springs, California, 92262, United States
CD02_OpenLabel Investigational Site

San Francisco, California, 94115, United States
CD02_OpenLabel Investigational Site

New Haven, Connecticut, 06510, United States
CD02_OpenLabel Investigational Site

Ft. Pierce, Florida, 34982, United States
CD02_OpenLabel Investigational Site

Miami, Florida, 33136, United States
CD02_OpenLabel Investigational Site

Miami, Florida, 33139, United States
CD02_OpenLabel Investigational Site

Miami, Florida, 33169, United States
CD02_OpenLabel Investigational Site

Orlando, Florida, 32803, United States
CD02_OpenLabel Investigational Site

West Palm Beach, Florida, 33401, United States
CD02_OpenLabel Investigational Site

Decatur, Georgia, 30033, United States
CD02_OpenLabel Investigational Site

Chicago, Illinois, 60613, United States
CD02_OpenLabel Investigational Site

Wichita, Kansas, 67214, United States
CD02_OpenLabel Investigational Site

Syracuse, New York, 13210, United States
CD02_OpenLabel Investigational Site

Bellaire, Texas, 77301, United States
CD02_OpenLabel Investigational Site

Houston, Texas, 77004, United States
CD02_OpenLabel Investigational Site

Houston, Texas, 77098, United States
CD02_OpenLabel Investigational Site

Spokane, Washington, 99202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.